Influence of a written or oral patient information program in daily clinical practice on adherence and persistence with an aromatase inhibitor in adjuvant primary breast cancer treatment in comparison to standart clinical care within outcome research.

Influence of a written or oral patient information program in daily clinical practice on adherence and persistence with an aromatase inhibitor in adjuvant primary breast cancer treatment in comparison to standart clinical care within outcome research. - The COMPAS-Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00004826

Enrollment

180

Registered

2013-03-19

Start date

2006-04-03

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer Compliance C50

Interventions

Group 1: Group 1 – no intervention, standard information Patients only got the baseline information in the hospital and the 12 and 24 months interviews (visits) Group 2: Group 2 – Patients received at

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: • Female • Primary breast cancer • Aromatase inhibitor therapy following German breast cancer guidelines [30] • Informed consent • Patient is capable of using oral medication on her own initiative following prescribing information

Exclusion criteria

Exclusion criteria: • Continuously hospitalized, staying in nursery home or receive support via an ambulatory home care service or similar • Suffer from any form of dementia or similar disease with interference of memory • Other disease or mental or physical disorder that, in the opinion of the study coordinator, would interfere with participation in the study • Known medical, drug or alcohol abuse.

Design outcomes

Primary

Measure	Time frame
proportion of patients classified “adherent” after 12 months; patients were classified adherent if both self-report and prescription refill revealed an adherence above 80%	—

Secondary

Measure	Time frame
Persitence, reasons for non-compliance,possible factors influencing adherence and persistence, reasons for non-adherence and discontinuation, influence of the interventions on other factors as knowledge and quality of life. Data was collected with questionaires combined with interviews at visits 0,12 and 24 months.	—

Countries

Germany

Contacts

Public ContactVolker Ziller

UKGM, Phillips-Universität Marburg

zilleri@med.uni-marburg.de064215866486

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026